Pontifax invests NIS 10m in Medical Compression Systems

MCS is developing a device for the prevention of blood clots in limbs following orthopedic surgery.

Pontifax has invested NIS 10 million in MCS Medical Compression Systems (DBN) Ltd. (TASE:MDCL), which is developing a device for the prevention of blood clots in limbs following orthopedic surgery. MCS will allot to Ponifax III Fund four million shares at NIS 2.50 per share and 1.2 million warrants, exercisable for 1.2 million shares, giving it an 8.7% stake in the company, and 11% stake if all the warrants are exercised.

MCS posted $4 million revenue for the first quarter of 2012, 11% more than for the corresponding quarter of 2011. Its operating and net loss were both $1.3 million, and it expects to continue losing money as it builds its market.

MCS is Pontifax's second investment so far this year in a public medical devices company, following a NIS 5.6 million investment in InsuLine Medical Ltd. (TASE: INSL). The investments suggest that the fund sees an upside at companies' current share prices, even though some companies already have sales.

"The investment shows that the device interests people in the pharmaceutical industry, and knows the drugs that we compete against," said MCS CEO Adi Dagan. "If our company succeeds, there will be no place for drugs for the prevention of post-surgical embolism."

MCS's share price rose 3.4% today to NIS 2.57, giving a market cap of NIS 113 million.

Published by Globes [online], Israel business news - www.globes-online.com - on August 14, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017